Online and face-to-face programmes to suit your CPD needs, apply now for September 2018
Page URL: https://www.bionews.org.uk/page_88872

US gene therapy trials set to resume

3 March 2003
By BioNews
Appeared in BioNews 197

Most US gene therapy trials that use viruses to deliver genes to bone marrow cells should be allowed to continue, Food and Drug Administration (FDA) advisors decided at a meeting held last Friday. Gene therapy trials for X-linked severe combined immune deficiency (X-SCID) were suspended in the US and several other countries, after two patients in a French trial developed leukaemia.The FDA also halted 27 other trials that use the same gene delivery system as the experimental X-SCID treatment. But at its meeting last week, the FDA's Biological Response Modifiers Advisory Committee (BRMAC) voted 19-1 in favour of allowing these studies to proceed, in cases where there are no other therapies available. This could also include X-SCID patients, although doctors 'would need to justify on a case by case basis that there were no acceptable alternatives' said Philip Noguchi of the FDA.

This decision mirrors the advice given by the US Recombinant DNA Advisory Committee (RAC) earlier this year.

Children affected by SCID have a faulty gene that means they have no working immune system, so their bodies cannot fight infections. Scientists at the Necker Hospital in Paris treated eleven X-SCID patients by using a virus to deliver a working gene to the immune cells in the bone marrow. But two of these boys, successfully treated soon after birth, subsequently developed symptoms of leukaemia at the age of three. No cases of leukaemia have been identified in X-SCID trials taking place elsewhere, or in any other gene therapy studies using the same virus delivery system. The X-SCID trial taking place at Great Ormond Street Hospital in London remains suspended, pending a joint meeting of the UK's Gene Therapy Advisory Committee and the Committee on the Safety of Medicines later this month.

SOURCES & REFERENCES
FDA advisors say most gene therapy studies can proceed
Reuters |  28 February 2003
FDA advisory committee discusses steps for potentially continuing certain gene therapy trials that were recently placed on hold
Food and Drugs Administration |  28 February 2003
Resumption of halted gene therapy trials backed
The New York Times |  1 January 1970
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
8 April 2005 - by BioNews 
A gene therapy technique that repairs faulty genes by 'editing' their DNA could lead to new treatments for inherited blood disorders and HIV, say US researchers. The approach could help address safety concerns over current gene therapy methods, many of which rely on specially adapted viruses to deliver working genes...
13 March 2005 - by BioNews 
Doctors at Great Ormond Street Hospital (GOSH) for Children and the Institute of Child Health have successfully treated a second disease using pioneering gene therapy treatment. The four-year old boy who received the therapy was affected by ada-SCID, a life-threatening immune deficiency condition. He is now attending pre-school and living...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.